(Q43008118)

English

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

scientific article published on October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

author name string

Luigi Rigacci

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Benedetta Puccini

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ida Chitarrelli

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Annalisa Chiappella

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Umberto Vitolo

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alessandro Levis

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Francesco Lauria

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Alberto Bosi

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

4573-4579

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of platinum-based lymphoma salvage regimens. The M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multice

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25216

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.25216

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43008118&oldid=1976521743"